Come up with a name for your new list and we'll add to it:
Viewpoint Molecular Targeting raised a round of funding on August 27, 2015. Investors include
National Cancer Institute.
Viewpoint Molecular Targeting develops pharmaceutical drugs for diagnostic imaging and therapy for cancer, with a focus on metastatic melanoma. Its novel image-guided therapies enable a personalized a…